Investor Partnering Forum at the CLS Innovation Showcase

CLS accepted pitch applications from California-based life sciences startups to meet with select investors participating in the partnering forum at the CLS Innovation Showcase on December 12 at SmartLabs at Oyster Point. Each participating investor will select up to six (6) companies for in-person conversations. Applying companies should be prepared to present in person in South San- Francsico at Smart Labs on December 12! Learn more about the showcase and register to attend here.

Thank you to everyone who applied! The application process has concluded. Acceptance notifications will be the week of November 20.

Learn more about these participating investment organizations:

AbbVie is dedicated to advancing cutting-edge science and technologies with the potential to create groundbreaking therapies in fields that strategically align with areas of interest. Target partnership meetings will include both formed and aspiring biotech companies that are actively developing next-generation drug modalities, including small molecules, biologics, gene therapies, in-vivo cell therapies, and platform technologies.

The specific therapeutic areas of interest include:

  • Oncology
  • Immunology
  • Neuroscience
  • Eye Care
  • Genetic Medicines (RNA & DNA, Delivery and Cargo)

Exclusions: Diagnostics, Devices, Research Tools, Nutrition, and Healthcare Services/IT

Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top caliber management teams building world-class companies. Since 1973, Abingworth has invested in over 180 life science companies, leading to 46 M&As and 70+ IPOs.

Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development.

Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. Abingworth became part of Carlyle (NASDAQ: CG) on 1 August 2022.

Investing in Revolutionary Technologies to Cure Disease, Improve Nutrition, and Enhance the Future of Human Health

Alexandria Venture Investments is the company’s strategic venture capital platform. Since our inception in 1996, we have invested in disruptive life science companies as well as promising agrifoodtech, climate innovation, and technology companies that are advancing transformative new modalities and platforms to meaningfully improve human health.

Our venture activity provides deep insights into key macro life science industry and innovation trends; builds and nurtures strong relationships with serial entrepreneurs, world-renowned academic institutions, and venture investors; and further enhances the high-quality tenant base we have diligently cultivated over many years.

Civilization Ventures: Empowering Biotech Innovations through Venture + Mentor Capital
Civilization Ventures invests in founders in the fields of biology and health care. Leveraging our vast network of life science experts, entrepreneurs and KOLs, we help accelerate the success of our founders through not just capital, but strategic guidance.

  • Pre-Seed & Seed Investment: Focused early-stage capital to kick-start your innovation
  • Series A + beyond: Funding to scale startup operations and market reach
  • Follow-On Investment: a new fund for helping our startups scale

Focus Areas:

  • Genomics and Diagnostics, including AI-driven platforms
  • Digital Health, including value-based care, telehealth, and health data analytics
  • Synthetic Biology, including gene editing, cell therapies, and regenerative medicine

Danaher Ventures is on a mission to apply the power of science and technology to improve human health. We are a strategic investor that invests in early-stage innovation across four platforms that drive our business: genomic medicines, bioprocessing, life science tools, and diagnostics. We are a trusted partner to entrepreneurs and global investors with our industry leading network of associates, global manufacturing and commercial footprint, scientific advisory board, and investors. Companies that we invest have privileged access to Danaher operating companies and open innovation partnerships including co-development, co-marketing, co-distribution, and more. We are powered by the Danaher business system with industry leading talent, driven by purpose and focused on long-term success.

Life Science Angels is one of the nation’s premier healthcare-focused angel investment organization for seed-early stage companies.
We have established two separate committees to review medical technology and biotechnology investment opportunities. The investment committees select the companies to present to our broader membership based on a rigorous due diligence process. Members make their own investment decisions, but the investments are made through a single LLC. Typical investments range from $200-$600k, with syndicated financings ranging to $2-3M.

LongeVC: Investing in an Ageless Future by Supporting Early Stage Founders
LongeVC invests in early stage founders in the fields of therapeutics, diagnostics and prevention and longevity infrastructure. Leveraging our experienced advisory board, KOLs, and Big Pharma partners, we bring breakthrough biotech to market — the science that will change lives and transform our health. We invest from Seed to Series A, and participate in Follow-On Investments to help companies reach their next major milestone inflection points.

Focus Areas:

  • Diagnostics and Prevention, including genomics and AI-driven platforms
  • Digital Health, including value-based care, telehealth, and health data analytics
  • Synthetic Biology, including gene editing, cell therapies, and regenerative medicine
  • Therapeutics, including pre-clinical and clinical stage drug development companies
  • Longevity Infrastructure, including foundational platform technologies for faster drug discovery and testing at scale.

OrbiMed is a leading healthcare investment firm with more than $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of more than 130 professionals is based in New York City; London; San Francisco; Shanghai; Hong Kong; Mumbai, India; Herzliya, Israel; and other key global markets. For more information, please visit Follow us on X (formerly Twitter) @OrbiMed.

Area of Interest:
Therapeutic companies that have compelling lead programs at drug candidate nomination, pre-clinical or clinical stage.

Pfizer Ignite is a new end-to-end service for biotech companies with high potential science that leverages Pfizer’s significant R&D capabilities, scale and expertise to accelerate the development of breakthrough therapies.

Through a suite of customized services that includes strategic advisory, research, development, and manufacturing, Pfizer Ignite tailors each collaboration to the partner’s unique needs and stage. Pfizer Ignite works with select biotechs, who are aligned with our priority therapeutic areas and are pre-clinical through Phase II and beyond.

Pfizer Ignite offers a variety of flexible agreement structures, which may include fee-for-service, strategic rights and/or equity.

Pfizer Ignite Offerings:

  • Expert Advisory Network
  • Pre-Clinical Research & Development
  • Clinical Development
  • Clinical Supply & Manufacturing
  • Multi-Sector Platforms

Pfizer Ignite’s focus areas include, but are not limited to:

  • Oncology (e.g., Breast, prostate, lung, bladder, colorectal, renal, melanoma and hematologic cancers)
  • Inflammation & Immunology (e.g., Rheumatology, Gastroenterology/Hepatology, Medical Dermatology)
  • Cardiovascular/metabolic disease (e.g., T2D, obesity)
  • Non-malignant hematological disease (E.g., Sickle Cell Disease, red cell health)
  • Anti-Infectives/Vaccines (e.g., flu, RSV)
  • Technology platforms with the potential to fuel multiple products
  • Data platforms (eg., AI/ML)

Phase Two Ventures | San Diego, California
Principals: Will Alaynick, PhD, José Morachis, PhD

Phase Two Ventures has made investments in Life Science deep tech tools, reagents and platform technologies to advance scientific discovery, technology development, and diagnostics.

Defined Bioscience, Inc.: Rationally designs and sells chemically-defined, animal product free cell culture media and growth factors for ES and iPSC stem cell culture. We can produce media in cGMP formats that support Cell & Gene Therapy process development and regulatory filings.
NanoCellect Biomedical, Inc.: Designs, builds and sell fluorescence-activated cell sorters (FACS) that use sterile, disposable microfluidic cartridges to support Cell Line Development and ‘Omics Sample Prep. Developing an Image Guided Cell Sorter that can sort cells based on labeled and label-free images to serve Cell & Gene Therapy discovery and process development.
Arima Genomics, Inc.: NGS kits and algorithms to capture long-range, phasing, and structural information that allows Illumina sequencing to map all 46 chromosomes in humans and detect chromosome fusions to find druggable driver mutations in clinical oncology diagnostics via Aventa Genomics testing.
Lynx Bio, Inc.: Clinical-stage biotechnology company combining physiologically relevant suspension cell co-culture assays, automated microfluidics, and deep learning analytics to rapidly advance drug candidates in oncology and bring personalized cancer treatments to patients.

Remiges Ventures is a US-based cross-border venture capital firm with offices in Seattle, Washington and Tokyo, Japan focusing on investments in early-stage drug discovery and therapeutic development companies.
Our mission is to support entrepreneurs to develop innovative therapeutics that help patients suffering from diseases with limited or no treatment options. Remiges Ventures operate on the following philosophy:

  • We support entrepreneurs pursuing the development of truly innovative drugs with the objective of promoting the commercialization of new therapies that bring hope to suffering patients.
  • We are a platform for the development of innovative drugs, connecting inventors, entrepreneurs, biotechnology, and pharmaceutical companies.
  • We support the ambitions of entrepreneurs seeking to start businesses in the development of innovative new drugs, globally.
  • Our investment philosophy is an important element in our ability to deliver a superior return while at the same time achieving our strategic objectives

The collective experiences of our team support our mission and portfolio companies to create therapies that address patients’ unmet medical needs and a culture that endures. Remiges is interested in meeting with entrepreneurs, scientists, and licensors with exciting innovations that will become the foundations of future therapies.

SR One is a venture capital firm on a mission to translate ground-breaking science into next generation medicines. We invest across therapeutic area and stage of development, with a focus on innovation and company building.

Our success as a firm is defined by the strength, diversity, and connectivity of our people, and our collective commitment to SR One’s mission of turning cutting-edge science into transformational medicines.

We possess extensive experience across science, company formation, investing, and operations, a toolkit which enables us to add value beyond capital to entrepreneurs. We have a long-standing history of making investments together, with over 60 of our investments executed and supported by the current Investment Committee.

We are based on both coasts of the US, as well as in London UK, and are proud to be deeply engrained in these key biotech hubs and work with seed and early stage biotech, pharma, and therapeutic R&D companies.

Xontogeny (zahn-TAH-juh-nee) is a life sciences accelerator that funds, supports and advances life science technologies from early development through clinical proof-of-concept. Our experienced leadership team elevates scientists and entrepreneurs by providing active mentorship, financing solutions and operational guidance to increase the probability of success in early drug development. We also have access to capital through the Perceptive Xontogeny Venture Funds to support companies seeking Series A and B financings.